Aigis Labs Ltd.

What Aigis Labs Ltd. does

Aigis Labs Ltd. is an Israel-based medical technology company developing advanced wound management and skin care products built around its proprietary NMBM (Natural Matrix Bio-Polymer Membrane) technology. Founded in 2007 and headquartered in Tel Aviv, the company has spent nearly two decades adapting agricultural fruit-wax coating chemistry for dermatological applications, creating a natural bio-polymer membrane designed to establish an optimal healing environment for chronic and acute wounds. The NMBM formula is protected by a US patent and has been clinically tested on over 100 patients across several leading dermatology centers in Israel, with successful hypoallergenic results.

The company's flagship commercial product is Dermaden™, a wound and burn treatment intended to accelerate healing and provide painless treatment for pressure wounds, bed sores, diabetic ulcers, severe burns, venous ulcers, and necrosis. Dermaden is distributed through clinical and medical sales channels targeting healthcare providers and institutions in wound care and dermatology, with quote-based pricing for institutional buyers and no publicly disclosed price list. Additional wound care and skin care cosmetic products are disclosed as in development, indicating an intention to extend the product portfolio. The company is privately held, founder-led, and has no disclosed institutional investors, funding rounds, or acquisitions in the available data.

Aigis Labs operates with a lean team of 11-50 employees, led by four executives: CEO Shay Cohen (Tel Aviv University MBA in technology management), VP R&D Itzik Mashiach (Technion-trained engineer with 10 medical device patents), CTO Uzi Lederman (Technion biochemistry engineer who has led NMBM development since 2007), and Chairman Doron Ben-Ami (former Merck AV and Lundbeck Israel GM). Commercial operations and clinical evidence are currently concentrated entirely in Israel, with no documented geographic expansion, distribution partnerships, or international regulatory filings. Revenue figures, funding totals, and customer counts are not disclosed.

Name

Aigis Labs Ltd.

Legal name

Aigis Labs Ltd.

Website

https://aigis-labs.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Aigis Labs Ltd. is an Israel-based medical technology company that develops advanced wound care and skin care products based on its proprietary NMBM bio-polymer membrane technology, with its flagship Dermaden product serving clinicians treating chronic wounds and burns.

Ownership category

akta.pro rank

Product category

Wound Care Products

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Wound care products
• Advanced wound management
• Dermatology treatments
• Burn care products
• Bio-polymer membrane

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Product Sales - Dermaden: Sale of Dermaden wound care product based on NMBM technology. Dermaden treats various wound types including pressure wounds, bed sores, diabetic ulcers, severe burns, and venous ulcers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Aigis Labs develops and sells Dermaden™, a wound and burn treatment product based on its patented NMBM (Natural Matrix Bio-Polymer Membrane) technology derived from natural fruit waxes adapted for dermatology. The product is sold to healthcare providers and clinicians for the treatment of pressure wounds, bed sores, diabetic ulcers, severe burns, venous ulcers, and necrosis, delivering faster healing and a painless treatment experience compared to standard wound care.

Product overview

Aigis Labs Ltd. is a wound management and skin care company founded in 2007, operating in the derma technology field. The company's portfolio centers on its proprietary NMBM (Natural Matrix Bio-Polymer Membrane) technology, a US-patented formula derived from natural waxes. The flagship commercial product is Dermaden™, a wound and burn treatment that uses the NMBM technology to accelerate healing. Additional wound care and skin care cosmetic products are currently in development.

Differentiator

Problem solved

Functional benefit

Brands

• Dermaden: Flagship wound and burn treatment product based on NMBM technology. Assists treatment of pressure wounds, bed sores, diabetic ulcers, severe burns, venous ulcers, and necrosis.

Products and services

• Dermaden™

Quantifiable outcome

• Clinically tested on over 100 patients with impressive clinical results versus standard treatments

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves5 records

Expansion highlights3 records

Broad incumbents

• Medline Industries:
• 3M Health Care (Solventum wound care): Diversified global healthcare and wound-care incumbent (now Solventum). Offers broad advanced dressings portfolio competing across all Dermaden indications, with deep hospital formulary penetration.
• Smith & Nephew (Advanced Wound Management): One of the largest wound-care incumbents with extensive advanced dressings, biologics, and negative-pressure wound therapy portfolios. Comparable across all Dermaden indications but at multinational scale.

Direct peers

• Coloplast: Danish medical device company with a major wound-care and skin-care business (Biatain, etc.). Directly comparable in advanced dressings for pressure ulcers, venous ulcers, and diabetic foot ulcers.
• Mölnlycke Health Care: Swedish wound-care and surgical solutions company with Mepilex and other advanced dressings. Direct competitor in chronic-wound and burn dressings sold through hospital channels.
• ConvaTec Group: Global wound-care specialist with portfolios in advanced dressings, skin substitutes, and ostomy. Direct overlap with Aigis Labs in chronic-wound and burn dressings, though at vastly larger scale.

Emerging players

• MiMedx Group: Regenerative medicine company focused on placental tissue allografts for wound care and surgical recovery. Comparable as a smaller, biologically-derived wound-therapy company.
• Organogenesis Holdings: US-based regenerative medicine company selling skin substitutes and biologic wound coverings (Apligraf, Dermagraft). Most direct peer for Aigis's biologic/regenerative membrane positioning.
• Integra LifeSciences: Specialty medical device company with regenerative skin and wound-care products (Integra Dermal Regeneration Template). Comparable as a smaller specialty player in skin substitutes and dermal matrices.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/aigislabs

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aigis Labs Ltd.